Evidence map›Paper›PMID 23383140›Full record

ArticlePloS one2013

Erythropoietin protects adult retinal ganglion cells against NMDA-, trophic factor withdrawal-, and TNF-α-induced damage.

Zhi-Yang Chang, Ming-Kung Yeh, Chiao-Hsi Chiang, Yi-Hao Chen, Da-Wen Lu

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 42 citations in OpenAlex.

  1. Article
  2. Mechanisms of Erythropoietin-Mediated Protection Against Retinal Ganglion Cell Apoptosis.Medical science monitor : international medical journal of experimental and clinical research · 2025
    Article
  3. Erythropoietin in Glaucoma: From Mechanism to Therapy.International journal of molecular sciences · 2023
    Review
  4. The Latest Evidence of Erythropoietin in the Treatment of Glaucoma.International journal of molecular sciences · 2022
    Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Erythropoietin in ophthalmology: A literature review.Journal of current ophthalmology · 2016
    Review
  18. Article
  19. Regeneration in the nervous system with erythropoietin.Frontiers in bioscience (Landmark edition) · 2016
    Review
  20. Erythropoietin and diabetes mellitus.World journal of diabetes · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Zhi-Yang ChangGraduate Institute of Life Sciences, National Defense Medical Center, Neihu, Taipei, Taiwan.
Ming-Kung Yeh
Chiao-Hsi Chiang
Yi-Hao Chen
Da-Wen Lu
National Defense Medical Center · TWTri-Service General Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study aimed to evaluate the neuroprotective effect of EPO in the presence of N-methyl-d-aspartate (NMDA)-, trophic factor withdrawal (TFW)-, and tumor necrosis factor-alpha (TNF-α)-induced toxicity on total, small, and large retinal ganglion cells (RGCs).

methodsRetinal cells from adult rats were cultured in a medium containing brain-derived neurotrophic factor (BDNF), ciliary neurotrophic factor (CNTF), basic fibroblast growth factor (bFGF), and forskolin. Expression of RGC markers and EPOR was examined using immunocytochemistry. RGCs were classified according to their morphological properties. Cytotoxicity was induced by NMDA, TFW, or TNF-α. RGC survival was assessed by counting thy-1 and neurofilament-l double-positive cells.

resultsEPO offered dose-dependent (EC₅₀ = 5.7 ng/mL) protection against NMDA toxicity for small RGCs; protection was not significant for large RGCs. Time-course analysis showed that the presence of EPO either before or after NMDA exposure gave effective protection. For both small and large RGCs undergoing trophic factor withdrawal, EPO at concentrations of 1, 10, or 100 ng/mL improved survival. However, EPO had to be administered soon after the onset of injury to provide effective protection. For TNF-α-induced toxicity, survival of small RGCs was seen only for the highest examined concentration (100 ng/mL) of EPO, whereas large RGCs were protected at concentrations of 1, 10, or 100 ng/mL of EPO. Time-course analysis showed that pretreatment with EPO provided protection only for large RGCs; early post-treatment with EPO protected both small and large RGCs. Inhibitors of signal transduction and activators of transcription such as (STAT)-5, mitogen-activated protein kinases (MAPK)/extracellular-regulated kinase (ERK), and phosphatidyl inositol-3 kinase (PI3K)/Akt impaired the protective effect of EPO on RGCs exposed to different insults.

conclusionEPO provided neuroprotection to cultured adult rat RGCs; however, the degree of protection varied with the type of toxic insult, RGC subtype, and timing of EPO treatment.

Indexed as

Analysis of VarianceAnimalsBrain-Derived Neurotrophic FactorCell CountCell Culture TechniquesCiliary Neurotrophic FactorColforsinCulture MediaDose-Response Relationship, DrugErythropoietinFibroblast Growth Factor 2ImmunohistochemistryMicroscopy, FluorescenceN-MethylaspartateRatsRetinal Ganglion CellsBrain-Derived Neurotrophic FactorCiliary Neurotrophic FactorColforsinCulture MediaErythropoietinFibroblast Growth Factor 2N-MethylaspartateTumor Necrosis Factor-alpha

Identifiers

PMID23383140
PMCPMC3559395
OpenAlexW2088449872

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.